Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21358976 | 1.00 | DPP4 (0.39) | DPP4DPP8DPP9MMP2ANPEP | |
| SCHEMBL27168395 | 1.00 | DPP4 (0.39) | DPP4DPP8DPP9MMP2ANPEP | |
| SCHEMBL2557543 | 0.79 | GAA (0.30) | — | |
| SCHEMBL14877013 | 0.79 | HPGD (0.33) | DPP4DPP8DPP9MAPT | |
| SCHEMBL27032619 | 0.79 | HPGD (0.33) | DPP4DPP8DPP9MAPT | |
| SCHEMBL2159514 | 0.79 | GAA (0.30) | — | |
| SCHEMBL15817157 | 0.79 | HPGD (0.33) | DPP4DPP8DPP9MAPT | |
| SCHEMBL17593010 | 0.79 | GAA (0.30) | — | |
| SCHEMBL18210060 | 0.78 | DPP4 (0.36) | DPP4DPP8DPP9MMP2ANPEP | |
| SCHEMBL20553900 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| EP-4159739-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2023-04-05 | — | — | EP | disclosed |
| CN-114929709-A | Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | 比奥根MA公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-108064224-B | Amide-substituted thiazoles as modulators of Ror gamma t | 詹森药业有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-106946867-B | FXR receptor modulators and its preparation method and application | 广州市恒诺康医药科技有限公司 | 2019-11-12 | — | — | CN | disclosed |
| EP-3401315-A1 | FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | Guangzhou Henovcom Bioscience Co. Ltd. (CN) | 2018-11-14 | — | — | EP | disclosed |
| CN-108064224-A | Amide-substituted thiazoles as modulators of Ror gamma t | 詹森药业有限公司 | 2018-05-22 | — | — | CN | disclosed |
| EP-3212641-A1 | THIAZOLES AS MODULATORS OF RORyt | Janssen Pharmaceutica NV (BE) | 2017-09-06 | — | — | EP | disclosed |
| CN-106946867-A | FXR receptor modulators and its production and use | 广州市恒诺康医药科技有限公司 | 2017-07-14 | — | — | CN | disclosed |
| WO-2016069976-A1 | THIAZOLES AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-06 | — | — | WO | disclosed |
| EP-2437599-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010141539-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2010-12-09 | — | — | WO | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| CN-101534824-A | Aminopyrrolidines as chemokine receptor antagonists | ABBOTT LAB (US) | 2009-09-16 | — | — | CN | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | DPP4 2706/4885DPP8 2140/4885DPP9 2316/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | DPP4 624/4885DPP8 647/4885DPP9 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.